In autoimmune diseases like muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG), tacrolimus has demonstrated the ability to suppress CD4 and CD8 T-cell proliferation and significantly reduce Th1 and Th17 responses. Here, CD4 is linked to autoimmune disease.